Hypomethylating agent (HMA) therapy use and survival in older patients with Chronic Myelomonocytic Leukemia (CMML) in the United States: A large population-based study May 5, 2017August 13, 2017 liorco70 http://d22fjzb79sfamb.cloudfront.net/MDS2017/thu/1700%20-%201830/Thu%2018%EF%80%A200.mp4 A. Zeidan (USA)